Case Report: Pulmonary metastases of malignant meningioma [version 2; referees: 2 approved, 2 approved with reservations]

Suhail Basunaid¹, Frits M.E. Franssen¹, Ryan Accord², Myrurgia Abdul Hamid³, Shekar Mahesh⁴, Brigitta G. Baumert⁵, Olaf E.M.G. Schijns⁶

¹Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands
²Department of Cardiothoracic Surgery, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands
³Department of Pathology, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands
⁴Department of Radiology, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands
⁵Department of Radiation-Oncology (MAASTRO), GROW (School of oncology), Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands
⁶Department of Neurosurgery, Maastricht University Medical Centre, Maastricht, 6202 AZ, Netherlands

Abstract

Meningioma accounts for approximately one-third of primary central nervous system tumors. Most meningiomas are benign, although up to one third are classified as atypical or malignant. We describe a 63-year Caucasian male presenting with pleural metastases from an intracranial meningioma. Distant metastases from meningiomas are infrequently found in clinical practice and mostly are associated with atypical or malignant meningiomas. There is no standard treatment; however surgical resection of both the primary and metastatic lesions is the safest therapy. The overall prognosis of atypical meningiomas is poor. Our patient died one week after discharge from our hospital.
Corresponding author: Suhail Basunaid (s.basunaid@mumc.nl)

How to cite this article: Basunaid S, Franssen FME, Accord R et al. Case Report: Pulmonary metastases of malignant meningioma [version 2; referees: 2 approved, 2 approved with reservations] F1000Research 2014, 2:222 (doi: 10.12688/f1000research.2-222.v2)

Copyright: © 2014 Basunaid S et al. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing interests: No competing interests were disclosed.

Case report

A 63-year-old Caucasian man was referred to our hospital for further analysis of slowly progressing pleural effusion with a history of cough and dyspnea. The patient had a long history of epilepsy and meningioma. He was working as head in a department of administration. He was married and had two healthy kids. As a medication he took Pantoprazol, Tegretol and Dorsolamide and had stopped smoking a long time ago.

Our patient was diagnosed with progression of a previous operated (Simpson’s resection) and postoperatively irradiated (30 x 2 GY with a total doses of 60 GY within the EORTC 22042 in a study context) atypical left parieto-occipital meningioma (WHO grade-II). Re-resection of the tumor (Simpson’s) was performed and histopathology showed a malignant meningioma (WHO grade-III). In the follow up after re-resection there was an obvious evidence of a residual tumour at the falk cerebri. One year later an asymptomatic re-recurrence was diagnosed (Figure 1A and B), for which conservative follow-up was performed without further surgical intervention. This was given in the form of re-irradiation with a total doses of 130 GY (60 GY given for the re-re-recurrent tumor at the resected area + additional 70 GY applied as an integrated boost with IMRT-technic for the residual tumor at the falk cerebri). This decision was taken due to the higher degree of aggressiveness of the malignant meningioma, as further surgical intervention would harm the patient rather than curing him.

A few months later the patient was hospitalized with dyspnea, fatigue, productive cough and anorexia. Multiple pleural masses were detected at a chest computer-tomography (CT) scan. Histopathology was consistent with malignant meningioma (WHO grade-III, Figure 2A), there was a high expression in the EMA staining, also in the AE1/AE3 staining (Figure 2B). The CD 45 and CD 68 were positive and MIB-1 showed high proliferation. Palliative chemotherapy was offered but refused by the patient. The patient is died one week after discharge from the hospital as a result of voluntary euthanasia as was the will of the patient (valid written declaration).

Discussion

Pulmonary and pleural metastases from an intracranial meningioma are very rare. Distant metastases from meningiomas are infrequently found in clinical practice and mostly associated with atypical or malignant meningiomas. Meningiomas mainly recur loco-regional or adjacent to the radiation treatment fields. There are only isolated case reports regarding pulmonary metastases from meningioma. Most lung metastases were incidentally detected by chest radiography or by CT-scans, because metastatic lesions are usually asymptomatic. The presence of pulmonary metastases appears to negatively affect survival in patients with recurrent meningioma.

Regarding the relationship between the intracranial location and invasion of the sagittal sinus of the tumor and the pleural metastases the route of dissemination is most probably the central venous route to heart and lungs. In previous case reports the lung was the most common extracranial metastatic site for intracranial meningioma. Our case was unusual because of the highly rate of recurrences and later the distant metastases. There is no standard treatment in the case of distant metastases.

In this case, histopathologic findings of the primary tumor revealed hypercellularity, wide necrosis, and brain invasion into the normal brain parenchyma. Pathology of the lesion from the left thoracic wall was consistent with malignant meningioma.

Other case studies described that treatment of pulmonary metastasis of malignant meningioma consisted of surgical resection for both the primary or metastatic lesions.

Figure 1. MRI and CT scanning of the original meningioma intra-cerebral and at distance metastasis intra-pleural. A: T1 weighted image after administration of Gadolinium based contrast fluid shows a large extra-axial enhancing lesion in the left parieto-occipital region with local mass effect. Note that the sagittal sinus seems to be invaded. B: Contrast enhanced T1 weighted image after administration of Gadolinium based contrast fluid showing a large resection cavity after the second operation and recurrent disease at the most upper margin of the resection plane with enhancing areas surrounding the sagittal sinus. C: Midthoracal CT slice in the transverse plane. Scan performed after i.v. administration of iodine contrast. The lesion is easily distinguished at the left ventral thoracal intrapleural space, slightly enhanced suggesting solid tissue. Some pleural fluid is also present.
Postoperative conventional radiation therapy has been recommended for prevention of local recurrence, especially when resection is subtotal. There are insufficient data regarding radiation therapy by meningiomas with distant metastases, palliative chemotherapy is the only option in the case of distant metastases, however data regarding the efficacy of this systemic treatment are unknown.

Informed consent
Written informed consent for publication of clinical details and clinical images was obtained from the next of kin.

Author contributions

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

Acknowledgments
At the completion of this Case study, I am very thankful to all contributors, who were very helpful and without their support this case study would have never come into its present form.

Figure 2. Histology staining of a biopsy of the solid intrathoracic lesion showing the same morphology as the intracranial meningioma. A: A specimen (HE-stained, 40x) showing histological resemblance between the intrathoracic lesion and the intracranial meningioma. B: Specimen (focal plus and local weak) showed high expression in the EMA-staining and also in the AE1/AE3-staining.
References

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text
Open Peer Review

Current Referee Status: ✔️  ❓ ✔️ ❓

Version 2

Referee Report 17 September 2014

doi:10.5256/f1000research.5568.r6157

Christine Marosi
Department of Oncology, Medical University of Vienna, Vienna, Austria

The authors added valuable information on the radiotherapy in relapse as requested, so there is one question remaining for me: was an intracranial relapse diagnosed after reirradiation? However I feel confident in approving the version 2.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

Author Response 23 Sep 2014

Suhail Basunaid, AZM/Maastricht University, Netherlands

Dear Christine Marosi

Thank you very much for your approval

Suhail

Competing Interests: no competing interests were disclosed.

Referee Report 10 September 2014

doi:10.5256/f1000research.5568.r6093

Daniel Vorobiof
Department of Medical Oncology, Sandton Oncology Centre, Johannesburg, South Africa

The authors have acted on the suggestions of the reviewers and improved the description of the case. The report adds to the list of uncommon spread sites from a malignant neurological tumor.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
**Competing Interests:** No competing interests were disclosed.

---

**Author Response 23 Sep 2014**

Suhail Basunaid, AZM/Maastricht University, Netherlands

Dear Daniel Vorobiof

Many thanks for your approval.

Suhail

**Competing Interests:** no competing interests were disclosed.

---

**Version 1**

Referee Report 21 August 2014

doi:10.5256/f1000research.2443.r5747

Antonio Santacroce
Department of Neurosurgery, Heinrich Heine University, Dusseldorf, Germany

Basunaid et al. report on a patient harboring a recurrent meningioma who developed pleural metastases. The primary tumour is reported to be an atypical meningioma WHO Gr II, which upon recurrence shows a malignant histology WHO Gr. III.

I share the opinion of Drs Marosi and Simon about the importance of continuing reporting such clinical cases due to the rarity of such tumour entities, even though, as reported by Dr Vorobiof "It doesn't add any further information and doesn't contribute any new knowledge, neither diagnostic nor therapeutic to the current available medical literature"

There are some points which should be clarified. To quote the authors:

"Our patient was diagnosed with progression of a previous operated and irradiated (60 GY) atypical left parieto-occipital meningioma (WHO grade-II). Re-resection of the tumor was performed and histopathology showed a malignant meningioma (WHO grade- III). After reoperation, re-irradiation (60GY + additional 70GY) was given."

Which radiation technique was used? It is not clear whether the radiation dose applied upon recurrence was only 60Gy with the boost, and if the “additional” 70 Gy is the cumulative dosage applied including the boost, or just the boost itself.

I would also recommend verifying in the literature whether radiation therapy has been offered for histologically confirmed metastatic extracranial lesions.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

---

**Referee Report 27 June 2014**

doi:10.5256/f1000research.2443.r5253

? **Christine Marosi**
Department of Oncology, Medical University of Vienna, Vienna, Austria

I fully agree with the reviewer from Bonn, Matthias Simon. Meningiomas grade III are fortunately rare and they do metastasize through vascular pathways. Of course a register of such cases would be a valuable tool to get an idea of the prevalence of such events. The case reported by Basunaid is a tragic one as the patient asked for euthanasia one week after dismissal from hospital. This shows that he could not be offered any therapeutic option able to provide enough solace for staying alive.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

---

**Author Response 27 Jun 2014**

**Suhail Basunaid**, AZM/Maastricht University, Netherlands

I would like to thank Dr. Marosi for her time spent on reviewing this case report, and the valuable comments given. I would like to leave my current version as it is. I completely agree regarding the facts about the rarity of the case and the termination by the euthanasia declaration.

**Competing Interests:** No competing interests were disclosed.

---

**Referee Report 16 January 2014**

doi:10.5256/f1000research.2443.r2861

? **Matthias Simon**
Department of Neurology, University of Bonn, Bonn, Germany

Basunaid *et al.* describe a patient with a recurrent meningioma who ultimately developed pleural metastases. The primary tumor was assigned to WHO grade II, and the recurrent tumor to grade III. While this paper by itself does not provide truly novel information, in my view such rare patients should be reported in the literature. This and similar reports will help to build a database which may at some point help to improve our understanding and management of rare conditions. The report may benefit from a more comprehensive and detailed (tabular?) review of the literature.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

**Author Response 27 Jun 2014**

**Suhail Basunaid, AZM/Maastricht University, Netherlands**

I would like to thank Dr. Simon for his time and valuable comment. I wish to leave my current version as it is.

**Competing Interests:** No competing interests were disclosed.

---

**Referee Report 29 October 2013**

**doi:** 10.5256/f1000research.2443.r2143

---

**Daniel Vorobiof**

Department of Medical Oncology, Sandton Oncology Centre, Johannesburg, South Africa

This case report documents an unusual spread of a malignant meningioma. It doesn't add any further information and doesn't contribute any new knowledge, neither diagnostic nor therapeutic to the current available medical literature.

I have read this submission. I believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

**Competing Interests:** No competing interests were disclosed.

---

**Reader Comment 06 Jun 2014**

**Suhail Basunaid, AZM/Maastricht University, Netherlands**

Dear Sir,

I am not sure if you consider this an unusual spread of malignant meningioma. There were at least 3 years between the time of discovering it (by accident after a fall from his bicycle) and the pulmonary involvement. I can understand that this case report might not be a unique case but I found myself obliged to report it. There is not enough knowledge in the literature regarding the therapeutic options for malignant meningioma with distance metastases. There was a declaration of euthanasia by our patient but things went too quickly and our patient died shortly after discharge before being able to make an accurate decision.

**Competing Interests:** No competing interests were disclosed.